ArticleClinical research in cardiology : official journal of the German Cardiac Society2021
Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Comparison of Efficacy and Safety Between Drug-Coated Balloons Versus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions in Large Vessels: A Study-Level Meta-Analysis of Randomized Control Trials.Cardiovascular drugs and therapy · 2024Pooled it
- Efficacy and safety of drug-coated balloon in the treatment of acute myocardial infarction: a meta-analysis of randomized controlled trials.Scientific reports · 2022Pooled it
- Drug coated balloons for coronary artery bifurcation lesions: A systematic review and focused meta-analysis.PloS one · 2021Pooled it
- Article
- Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Strategy in Stable Angina and Acute Coronary Syndrome: A Propensity-Score Overlap-Weighted Analysis.Journal of clinical medicine · 2026Article
- Current and future role of drug-coated balloons in the treatment of coronary artery disease.Future cardiology · 2026Article
- Drug-Coated Balloons in All-Comer Population-Are We There Yet?Journal of clinical medicine · 2025Review
- Leaving Nothing Behind: Expanding the Clinical Frontiers of Drug-Coated Balloon Angioplasty in Coronary Artery Disease.Journal of cardiovascular development and disease · 2025Review
- Assessment of Scoring Balloons in STEMI Patients Treated With DCB-Only Angioplasty: A Single Center Study.Health science reports · 2025Article
- Drug-Coated Balloons for Coronary Interventions: A Focused Review.Methodist DeBakey cardiovascular journal · 2025Review
- Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.Cardiology journal · 2025Review
- Coronary Artery Dissection Series - Back to the Future II: The ARM Strategy (Avoid, Recognize and Manage Dissections) in Drug-coated Balloon Angioplasty.Heart international · 2025Article
- Safety aspects ofFrontiers in cardiovascular medicine · 2025Article
- Review
- One-Month Duration Compared with Twelve-Month Duration of Dual Antiplatelet Therapy in Elective Angioplasty for Coronary Artery Disease: Bleeding and Ischaemic Outcomes.Journal of clinical medicine · 2024Article
- Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- Long-Term Clinical Outcomes of Drug-Coated Balloon Treatment for De Novo Coronary Lesions.Yonsei medical journal · 2023Article
- Drug Coated Balloon in the Treatment of De Novo Coronary Artery Disease: A Narrative Review.Journal of clinical medicine · 2023Review
- Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study.Journal of cardiovascular development and disease · 2023Article
- Circulating intermediate monocytes CD14++CD16+ are increased after elective percutaneous coronary intervention.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to investigate long-term survival of paclitaxel DCB for percutaneous coronary intervention (PCI).
backgroundSafety concerns have been raised over the use of paclitaxel devices for peripheral artery disease recently, following a meta-analysis suggesting increased late mortality. With regard to drug-coated balloon (DCB) angioplasty for coronary artery intervention however, there is limited data to date regarding possible late mortality relating to paclitaxel.
methodsWe compared all-cause mortality of patients treated with paclitaxel DCB to those with non-paclitaxel second-generation drug-eluting stents (DES) for stable, de novo coronary artery disease from 1st January 2011 till 31st December 2018. To have homogenous groups allowing data on safety to be interpreted accurately, we excluded patients with previous PCI and patients treated with a combination of both DCB and DES in subsequent PCIs. Data were analysed with Kaplan-Meier curves and Cox regression statistical models.
resultsWe present 1517 patients; 429 treated with paclitaxel DCB and 1088 treated with DES. On univariate analysis, age, hypercholesterolaemia, hypertension, peripheral vascular disease, prior myocardial infarction, heart failure, smoking, atrial fibrillation, decreasing estimated glomerular filtration rate (eGFR) [and renal failure (eGFR < 45)] were associated with worse survival. DCB intervention showed a non-significant trend towards better prognosis compared to DES (p = 0.08). On multivariable analysis age, decreasing eGFR and smoking associated with worse prognosis.
conclusionWe found no evidence of late mortality associated with DCB angioplasty compared with non-paclitaxel second-generation DES in up to 5 years follow-up. DCB is a safe option for the treatment of de novo coronary artery disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.